ISPOR 2026 · Pennsylvania Convention Center · May 17-20, 2026
Evidence in Motion
A complete offering of
RWE solutions to meet your needs at any stage of the product lifecycle.
Our comprehensive approach addresses key stakeholder needs by developing integrated evidence generation strategies to provide a road map going forward.
Evidence Generation Consulting
- Integrated Evidence Generation Planning (IEGP) & Roadmap Development
- Value Story Creation
- Epidemiology Services
- HEOR Services
Modernized Study Design & Execution
- Decentralized and Hybrid Studies
- Patient & Site Recruitment
- Real-World Data Acquisition & Technology
Late-Stage Research
- Registration & Marketing Authorization
- Post Marketing Requirements (FDA PMR / EMA PASS)
- Line Extension
- Label Expansion
- Publication Strategy
- Expanded Access Prior to Approval
- Market Access to Support HTA Decision Making
JOIN US AT ISPOR 2026
Join our UBC team at
ISPOR 2026
ISPOR is the leading professional society for health economics and outcomes research (HEOR) globally. The Society’s mission is to advance HEOR excellence to improve decision making for health globally.
Our team at ISPOR looks different this year. Since Evidinno joined UBC in January, our Evidence Development Solutions group has meaningfully expanded — evidence synthesis, HEOR, medical writing, and outcomes research now sit alongside our RWE and observational study capabilities under one roof.
Dates
May 17-20
Location
Philadelphia, PA
Venue
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107
Our Team at AXS26
Meet Our Evidence Development Team
Schedule time with our team at ISPOR.
Aaron Berger
Senior Vice President, Head of Evidence Development
Mir Sohail Fazeli, MD, PhD
Vice President Product and Innovation
Founder & CEO at Evidinno Outcomes Research Inc.
Brett Huselton
Senior Vice President, Partnership, Innovation
& Strategic Solutions
Jersino Jean-Marie
Michael del Aguila
VP, Sales, Evidinno Outcomes Research Inc.
Masoud Pourrahmat
Executive Director and Head Of Operations at Evidinno Outcomes Research Inc.
Ali Shajarizadeh, PhD
Director of Health Economics, Evidinno Outcomes Research Inc.
Irene Cosmatos
Sr Director – Clinical Research
Irene Pan
Senior Epidemiologist
Samuel Igweokpala
Associate Epidemiologist
Joe Devine
Executive Director, Business Development
Christopher Broucek
Director, Business Development
Brendan Fowler
Executive Director, Business Development
UBC Performs Comprehensive RWD Feasibility Assessments
According to Regulatory Guidelines
Having Access to Data Doesn’t Mean it’s Fit-for-Purpose
Two-Phase approach
Initial scan assesses potential to meet study needs and narrow down options; subsequently, more comprehensive assessment of the candidate data sources is done.
Regulatory Readiness Considerations
Evaluation includes data traceability, governance, auditability, and timeliness to meet regulatory standards.
Methodology
Systematic feasibility assessments that align with regulatory guidelines produce well- documented assessments regulators can verify.
The UBC Difference
AI-powered evidence. Decision-ready results.
UBC delivers AI-powered systematic literature reviews and full-spectrum evidence development—with the scientific rigor regulators demand.
AI-Powered Evidence Synthesis
Systematic literature reviews in weeks, not months. AI-assisted screening with PRISMA-compliant methodology
Speed & Scientific Rigor
Every deliverable reviewed by PhD epidemiologists, biostatisticians, and health economists Zero junior-level work.
A Strategic Advantage
Full-spectrum evidence partner from SLR through HEOR, market access, RWE, and post-market surveillance.
A Unified Approach With Evidinno
We replace fragmentation with a single, AI-powered platform that combines technology with PhD-level scientific expertise to deliver regulatory-grade evidence at unprecedented speed.
What Makes Our Approach Different?
The Core of Our Solution
Full Spectrum Integration
Combine Evidinno’s HEOR and evidence synthesis expertise with UBC’s RWE, REMS, patient access, and post-market infrastructure — one integrated partner.
AI-Powered SLR
AI-assisted screening and extraction dramatically accelerates systematic literature reviews while maintaining PRISMA compliance and full reproducibility.
Regulatory Grade Quality
Deliverables built for FDA, EMA, Health Canada, CDA-AMC, and NICE submissions. Every output validated by PhD scientists with zero junior-level work.
Complex Analytics
Precision for every dataset.
NMA, ITC, predictive modeling, surrogate endpoint analyses, and health economic modeling (BIM, CEA, CUA) — advanced methods for your toughest evidence needs.
